Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
The GLP-1 receptor agonists approved for weight loss include: Zepbound (tirzepatide), Saxenda (liraglutide), and Wegovy (semaglutide)
Phase 2 trials showed up to 24.2% weight loss at 48 weeks, more than any other GLP-1 class medication tested so far
By activating GLP-1 receptors, it stimulates insulin secretion from pancreatic beta cells, leading to better glucose utilization and reduced blood sugar levels
Retatrutide is still undergoing trials and is not legally available for purchase anywhere
Ozempic (semaglutide) arrived later, produces substantially greater weight loss, and requires only weekly injections
doi: 10.1210/jcem.80.3.7883856 32 De MeesterIKoromSVan DammeJScharpS
US$ 24.58
US$ 20.04
US$ 28.43
US$ 29.20
US$ 26.55
US$ 26.91
